stem cells Archives - Page 6 of 70

Postdoc Job Opening: Cancer & Stem Cell Epigenomics Knoepfler Lab

July 5, 2017 / Professor Paul Knoepfler, Ph.D.

An NIH and foundation-funded postdoctoral fellow position in the Knoepfler Lab at UC Davis School of Medicine is open. The focus of research will be on cancer and stem cell epigenomics. Studies will include functional genomics assays such s ChIP-Seq, chromatin configuration, CRISPR genetics work, and cell biological research. Qualifications: Applicants must have a PhD, […]

Postdoc Job Opening: Cancer & Stem Cell Epigenomics Knoepfler Lab Read More »

Cynata stem cell trial update: CEO Ross Macdonald interview

July 3, 2017 / Professor Paul Knoepfler, Ph.D. / 2 Comments

Koch-et-al_2016_MCA-derived-MSC-Treatment-of-Hindlimb-Ischemia-in-Mice-e1498668676851

Stem cell clinical trials have a certain gravitational pull for me as I’m always fascinated by them and since the new Cynata trial is moving forward, I recently did an interview their CEO, Dr. Ross A. Macdonald to find out more. PK: Cynata’s recently initiated clinical trial aims to treat GVHD as have other stem

Cynata stem cell trial update: CEO Ross Macdonald interview Read More »

Movers & Shakers in Stem Cell & Regenerative Medicine Field

July 2, 2017 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Stem Cell & Regenerative Medicine field researchers move around to different places fairly often. It is interesting to note trends and also see who received what kinds of awards and such. Below is a list of some recent movers and shakers. George Daley got the ISSCR Public Service Award (you can see other ISSCR Awards here).

Movers & Shakers in Stem Cell & Regenerative Medicine Field Read More »

Highlights of ISSCR2017 – A Biomedical Engineer’s Perspective

June 25, 2017 / Professor Paul Knoepfler, Ph.D.

ISSCR meeting review By Agnes Soos Amid the hustle and bustle of downtown Boston, nearly four thousand researchers and exhibitors gathered for the 15th Annual ISSCR Meeting. With presentations from over thirty plenary lectures, and dozens of others featured in concurrent sessions and the daily Innovation Showcases, there definitely was no shortage of exciting research

Highlights of ISSCR2017 – A Biomedical Engineer’s Perspective Read More »

US Stem Cell bid for FDA RMAT rejected?

June 22, 2017 / Professor Paul Knoepfler, Ph.D. / 3 Comments

Can a stem cell clinic business get FDA RMAT designation? At least one announced it was trying, but now seems to have given up. Stem cell clinic business US Stem Cell, Inc. has reportedly announced that it is at least temporarily abandoning its efforts at getting Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The

US Stem Cell bid for FDA RMAT rejected? Read More »

Hunting for computational approaches for stem cells at ISSCR2017

June 20, 2017 / Professor Paul Knoepfler, Ph.D. / 7 Comments

By Cátia Bandeiras, PhD Student at University of Lisbon, Portugal and Massachusetts Institute of Technology. See tweets from the conference using #ISSCR2017 @apulgarita I just wrapped up my stay at the Annual Meeting of ISSCR 2017, which happened in Boston. I decided to take advantage of the fact that I am living in Boston at

Hunting for computational approaches for stem cells at ISSCR2017 Read More »

3 CIRM challenges: search for new prez, funding, & clinical POW!

June 19, 2017 / Professor Paul Knoepfler, Ph.D.

The idea of CIRM as a dedicated state stem cell agency was one of the things that got me excited about starting my time as a professor doing research on stem cells in California way back in 2005-2006 on the job hunt. Fast forwarding to today now 11 years later, CIRM is still on the

3 CIRM challenges: search for new prez, funding, & clinical POW! Read More »

FDA warp speed RMAT approval nukes stem cell clinic excuses

June 15, 2017 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Many stem cell clinics are in a bind in 2017 in the new RMAT approval reality. Stem cell clinics say that they only want to help people by providing stem cell therapies to patients in a speedier way that they claim getting FDA approval for a trial just doesn’t allow, but that doesn’t ring true.

FDA warp speed RMAT approval nukes stem cell clinic excuses Read More »

My talk on IPS cells at Future of Genomic Medicine mtg

June 11, 2017 / Professor Paul Knoepfler, Ph.D.

1000-genomes-consortiumpropertybildbereichbiospracheen

My talk on IPS cells at Future of Genomic Medicine mtg Read More »

Bioquark “reawaken” the dead with stem cells plan just zombie fodder?

June 6, 2017 / Professor Paul Knoepfler, Ph.D. / 2 Comments

A company called Bioquark reportedly claims it intends to bring back the dead, as in deceased people or at least brain dead people, with stem cells. Or at least awaken their brains. If it works, would those people be like zombies? Is it ethical to experiment in this way on dead people? Bioquark We first

Bioquark “reawaken” the dead with stem cells plan just zombie fodder? Read More »

stem cells

Subscribe to Our Newsletter